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“Do the stuff that only you can do. 
The urge, starting out, is to copy. And that is not a bad thing. 
Most of us only find our own voices after we’ve sounded like a lot of 
other people. But the one thing that you have that nobody else has is you. 
Your voice, your mind, your story, your vision” 
(Unknown) 
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ABSTRACT 
Cancer is one of the commonest causes of patient death in the clinic and a complex 
disease occurring in multiple organs per system, multiple systems per organ, or both, in the 
body. With increasing evidence that the interaction and network between genes and proteins 
play an important role in investigation of cancer molecular mechanisms to integrate systems 
biology, bioinformatics and computational science to improve diagnosis, therapies and 
prognosis of diseases. Cancer bioinformatics is a critical and important part of the systems 
clinical medicine in cancer and the core tool and approach to carry out the investigations of 
cancer in systems clinical medicine.   
Cancer involves uncontrolled cell division and tissue invasiveness (metastasis) 
caused by a series of mutations in the genes of proteins that regulate the cell cycle. Proto-
oncogenes are normal genes that promote cell growth and mitosis, whereas tumor 
suppressor genes repress cell growth. Proto-oncogenes can be mutated by carcinogens to 
become oncogenes that produce excessive levels of growth promoting proteins. Tumor 
suppressor gene products, typified by p53, is frequently transcription factors that suppress 
mitosis and cell growth to allow DNA repair. Activated p53 promotes cell cycle arrest to 
allow DNA repair and/or apoptosis to prevent the propagation of cells with serious DNA 
damage through the transactivation of its target genes implicated in the induction of cell 
cycle arrest and/or apoptosis. Poly (ADP-ribose) polymerase-1 (PARP1) is a chromatin-
associated enzyme with key functions in the regulation of transcription, cell cycle, 
tumorigenesis, and cellular response to DNA damage. PARP1 is activated by DNA damage 
and has important roles in DNA base excision repair (BER), functioning as a nick sensor, 
recruiter, and modulator of key DNA repair molecules. Notably, p53 and PARP-1 are in 
transcriptional repressive complexes which is involved in epigenetic phenomenon of cancer. 
This study is focusing on anti-cancer drugs using 5-aza-2'-deoxycytidine (5-Aza-
dC). The 5-Aza-dC is FDA-approved widely used hypo-methylating anticancer drug. We 
conducted an analysis for new functions of 5-Aza-dC by applying bio-chemo-informatics 
approach. Induction of p53 by 5-Aza-dC was tested in vitro using cancer cells.  While 
Bioinformatics analysis was used to predict protein target and its biological activity. It was 
predicted that 5-Aza-dC functions as a p53 inducer, radiosensitizer, and inhibitor of some 
enzymes and its protein target including MDM2, POLA1, POLB, and CXCR4 that are 
involved in the induction of DNA damage response and p53-HDM2-p21 signaling. In this 
study, we provide experimental evidence showing HDM2 is one of the targets of 5-AZA-
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dC leading to activation of p53 pathway and growth arrest of cells. Furthermore, we found 
that the combinatorial treatment of 5-AZA-dC with three other drugs caused drug resistance. 
We discuss that 5-Aza-dC-induced senescence is a multi-module drug that controls cell 
proliferation phenotype.  
Taken together our result proves novel evidence of bioinformatics and experimental 
analysis combination to support new insight for cancer therapeutic and to understand the 
specific molecular target even better.  
 
Key words: 5-Aza-dC,  anti-cancer, Bioinformatics. 
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1. Introduction 
 
1.1 Bioinformatics 
 Bioinformatics is simply defined as computational approach of molecular biology. 
This is the application of computer science and information to the field of biology and 
medicine. Bioinformatics is including how information is generated, transmitted, received, 
and interpreted in biology system [1]. The term of Bioinformatics for biologist is very huge 
including data analysis, data curator, database developer, statistician, software developer 
and many more. Need to be noted that appropriate software and web server selection is the 
key for computational biology. Here, Bioinformatics approach to support cancer 
therapeutics and many diseases will be explained including how to predict protein target, 
molecular modelling, docking analysis and interpretation data [2]. 
 Protein–protein interactions (PPIs) play a central role in all biological processes. 
These processes result from the physical interaction of several protein molecules, thus 
forming the macromolecular assemblies that effectuate cellular function [3-6]. Many large-
scale studies focusing on PPI have emerged in recent years, using graphs with nodes and 
edges to represent the protein components interacting with each other. Such binary 
representations capture a wealth of information but are inherently abstract and incomplete, 
since they contain no information as to time, place, or specificity. Such detailed information 
is indispensable for the guidance of mutagenesis studies or the design of inhibitor molecules. 
Protein–protein docking actually predates protein–ligand (small molecule) docking, that 
later extended to the interaction between macromolecules and small ligands [7]. The 
treatment of flexibility in the binding process is considerably easier with small molecules, 
even though a considerable computational cost is involved, and small molecule docking has 
become one of the most active research areas in computational drug discovery. Most if not 
all of present-day protein–protein docking algorithms have been developed in light of the 
critical assessment of prediction of interactions (CAPRI) experiment, which is a 
community-wide collaboration that has accelerated the development of computational 
protein docking methods [8-10]. CAPRI, which is modelled after critical assessment of 
protein structure prediction, organizes blind prediction trials; participants model their 
complex, and the models are assessed through comparison with an unknown crystal 
structure, made available to the assessors on a confidential basis and prior to publication. 
The early years have been essential for the development of docking algorithms, with the 
13 
 
incorporation of more elaborate scoring functions owing to efficient implementations of fast 
Fourier transform algorithms in docking as one of the key advancements. This also spawned 
the CAPRI [11]. 
 The PPI interfaces have received increased attention during the past years. A 
prediction of the residues involved in the interaction interface may be used to guide the 
docking itself. Subsequent optimization of the interaction interface requires modification of 
side chain orientation; protein docking algorithms increasingly include flexibility treatments 
in their docking procedures, and more recent implementations favour the simultaneous 
docking of ensembles of unbound conformers [12]. Together, the reliable prediction of 
interface residues and the incorporation of global and local flexibility in the docking 
algorithms provide invaluable information to inform mutagenesis studies and to steer drug 
design applications. The scoring functions of docking programs have been successfully 
improved with additional descriptors based on residue interaction networks (RINs). RINs 
consist of networks generated from three-dimensional structures, where nodes correspond 
to residues and edges to detected interactions. RINs are small-world networks, and their 
topological analyses have been used in particular to study protein–protein interfaces107 and 
protein– ligand binding and to optimize scoring functions for the evaluation of docking 
poses. Using different approaches, it has been demonstrated that combining the network 
measures such as closeness centrality, between centrality, degree, or clustering coefficient 
with energy terms can improve the ranking in scoring functions [13].  
 Two different types of RINs, a hydrophobic one and a hydrophilic one, for each 
complex, and then calculated a network-based score considering the average degrees and 
clustering coefficients. They developed a scoring method that enhanced discrimination of 
the scoring method of RosettaDock112 by .10% on a subset of protein–protein docking 
benchmark 2.0.113 The RIN of each protein individually before docking and calculated four 
measures of the network, including closeness centrality. By integrating a score based on the 
closeness values into the pyDock scoring function, they improved by as much as 36% the 
top ten success rate on the protein–protein docking benchmark 4.0.115 Furthermore, residue 
centrality analyses which are based on the average shortest path length, can also be used on 
docked poses to evaluate the central residues located in the interface. These residues could 
subsequently be targeted for mutagenesis experiments or drug design [14]. 
 The Interactome3D120 web service incorporates structural data into PPI networks to 
improve them with interface information. These structural data either come from 
experiments or are modelled through a comparative modelling pipeline. The value of this 
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tool by showing it allowed them to suggest a potential mechanism of action common to 
several disease-causing mutations. Indeed, they observed the mutations on structures of the 
complement cascade pathway involving, in particular, the complement component 3 (C3) 
and the component factor H (CFH) interaction [15].  Several disease-causing mutations 
were located at the interface of proteins, and these key elements could be targeted by drugs 
in order to stabilize the C3–CFH interface. Thus, with this type of network, it is possible to 
contextualize mutations related to different diseases involved in a pathway and draw 
potential links between them. It can help to better define the target to aim for and, hence, 
improve the drug design. Docking predictions could then be additionally integrated to these 
networks.  
 Furthermore, it was predicted that on average a drug binds to six different targets, 
including both the primary target and additional “off-targets”. Following this idea, reverse 
docking can be performed, which consists in the screening of one single molecule against 
multiple receptors instead of screening multiple small molecules against several receptors. 
Homology modelling may be useful to enrich the screening, when experimental structures 
are not available. The building of structural PPI networks may then be used in drug design 
to predict the targets the drug may bind to, with their related potential adverse drug 
reactions. They can help to identify which proteins would be affected by a drug designed to 
disrupt a particular interface because they highlight the domains that are involved in PPI. 
These structural PPI networks can also be exploited for drug repositioning, considering the 
use of known approved drugs or the reconsideration of late-stage failures [16]. 
 
 
1.2 Cancer and cell senescence 
 Cellular senescence refers to the essentially irreversible arrest of cell proliferation 
(growth) that occurs when cells experience potentially oncogenic stress. The permanence 
of the senescence growth arrest enforces the idea that the senescence response evolved at 
least in part to suppress the development of cancer [17]. The senescence arrest is considered 
irreversible because no known physiological stimuli can stimulate senescent cells to re-enter 
the cell cycle. However, molecular biological manipulations, for example, the sequential 
inactivation of certain tumor suppressor genes, can cause senescent cells to proliferate. 
There may be as-yet-unrecognized physiological circumstances under which the senescence 
growth arrest is reversible [18]. Normal cells do not divide indefinitely due to a process 
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termed cellular or replicative senescence. Several lines of evidence suggest that replicative 
senescence evolved to protect higher eukaryotes, particularly mammals, from developing 
cancer. Senescent cells differ from their pre-senescent counterparts in three way: 1) they 
arrest growth and cannot be stimulated to re-enter the cell cycle by physiological mitogens; 
2) they become resistant to apoptotic cell death; 3) they acquire altered differentiated 
functions. Replicative senescence occurs because, owing to the biochemistry of DNA 
replication, cells acquire one or more critically short telomere. The mechanism by which a 
short telomere induces the senescent phenotype is unknown. Recent findings suggest that 
certain types of DNA damage and inappropriate mitogenic signals can also cause cells to 
adopt a senescent phenotype. Thus, cells respond to a number of potentially oncogenic 
stimuli by adopting a senescent phenotype. These findings suggest that the senescence 
response is a fail-safe mechanism that protects cells from tumorigenic transformation [19].  
 Despite the protection from cancer conveyed by cellular senescence and other 
mechanisms that suppress tumorigenesis, the development of cancer is almost inevitable as 
mammalian organism’s age. Certainly, aging predisposes cells to accumulate mutations, 
several of which are necessary before malignant transformation occurs, particularly in 
humans. However, many benign or relatively well-controlled tumors may also harbor many 
potentially oncogenic mutations, suggesting that the tissue microenvironment can suppress 
the expression of many malignant phenotypes. Although the idea remains controversial, 
cellular senescence has also been proposed to contribute to organismal aging [20]. 
Senescent cells have recently been shown to accumulate with age in human tissues. One 
possibility is that the tissue microenvironment is disrupted by the accumulation of 
dysfunctional senescent cells. Thus, mutation accumulation may synergize with the 
accumulation of senescent cells, leading to increasing risk for developing cancer that is a 
hallmark of mammalian aging. 
 Aging hallmarks can be divided into three categories: (1) primary, or the causes of 
age-associated damage; (2) antagonistic, or the responses to the damage; and (3) integrative, 
or the consequences of the responses and culprits of the aging phenotype. Senescence, a 
cellular response that limits the proliferation of aged or damaged cells belongs to the 
antagonistic class [21]. Although senescence plays physiological roles during normal 
development and it is needed for tissue homeostasis, senescence constitutes a stress 
response triggered by insults associated with aging such as genomic instability and telomere 
attrition, which are primary aging hallmarks themselves. There is also an intimate link 
between senescence and the other antagonistic hallmarks of aging. For example, senescent 
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cells display decreased mitophagy, resulting in an “old,” defective mitochondrial network 
that may contribute to metabolic dysfunction in age [22]. 
 Regardless, the senescence arrest is stringent. It is established and maintained by at 
least two major tumor suppressor pathways the p53/p21 and p16INK4a/pRB pathways—
and is now recognized as a formidable barrier to malignant tumorigenesis. Consistent with 
this view, cells undergo senescence in response to a host of potentially oncogenic stimuli 
[23]. Cellular senescence entails widespread changes in chromatin organization, including 
the formation of repressive heterochromatin at several loci that encode pro-proliferative 
genes. Perturbations to the epigenome can elicit a senescence response (Figure 1). For 
example, global chromatin relaxation (such as that caused by broad-acting histone 
deacetylase inhibitors) induces senescence, often by depressing the p16INK4a tumor 
suppressor, which promotes the formation of senescence-associated heterochromatin. Other 
inducers, for example, suboptimal c-MYC or p300 histone acetyltransferase activity, also 
appear to act by perturbing chromatin organization and inducing p16INK4a expression. 
Notably, p16INK4a, which is expressed by many senescent cells, is both a tumor suppressor 
and a biomarker of aging. Finally, under some circumstances, epigenomic perturbations can 
elicit a DDR in the absence of physical DNA damage. For example, histone deacetylase 
inhibitors activate the DDR protein ATM which initiates a DDR without DNA damage. 
 Chronic activation or overexpression of p53, pRB, p21, or p16INK4a is generally 
sufficient to induce a senescence growth arrest. The p53/p21 and p16INK4a/pRB pathways 
also regulate several although not always all other features of senescent cells. Genomic 
damage, including dysfunctional telomeres, activates the DDR, which engages the p53/p21 
pathway [24-25]. This engagement is biphasic. The initial response is rapid (generally 
within minutes to an hour), robust, and transient (generally subsiding within 24–48 h), 
which is typical of the p53 response to many forms of DNA damage. However, if the 
damage is severe or irreparable enough to elicit a senescence response low-level p53 
activation and p21 expression persist once the robust rapid phase declines. Persistent DDR 
signaling appears to initiate the senescence growth arrest (as opposed to a transient damage-
induced growth arrest). Such signaling is also accompanied by the slow (occurring over 
days) activation of other signaling pathways, such as those governed by the stress-
responsive p38MAPK and protein kinase C pathways, and increased reactive oxygen 
species, which also participate in signaling pathways. These pathways are initiated by 
poorly understood mechanisms. These additional signaling pathways, then, stimulate the 
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expression of p16INK4a, which, acting through pRB, ensures the essential irreversibility of 
the growth arrest [26]. 
 
 
1.3 Apoptosis in cancer   
 Apoptosis is a very tightly programmed cell death with distinct biochemical and 
genetic pathways that play a critical role in the development and homeostasis in normal 
tissues. It contributes to elimination of unnecessary and unwanted cells to maintain the 
healthy balance between cell survival and cell death in metazoan. It is critical to animal’s 
especially long-lived mammals that must integrate multiple physiological as well as 
pathological death signals. Evidence indicates that insufficient apoptosis can manifest as 
cancer or autoimmunity, while accelerated cell death is evident in acute and chronic 
degenerative diseases, immunodeficiency, and infertility. Under many stressful conditions 
like precancerous lesions, activation of the DNA damage checkpoint pathway can serve to 
remove potentially harmful DNA-damaged cells via apoptosis induction to block 
carcinogenesis [27]. Thus, the apoptotic signals help to safeguard the genomic integrity 
while dysregulation of the apoptotic pathways may not only promote tumorigenesis but also 
render the cancer cell resistant to treatment. Thus, the evasi on of apoptosis is a prominent 
hallmark of cancer. Cancer cells are, in fact, harbouring alterations that result in impaired 
apoptotic signaling, which facilitates tumour development and metastasis [28]. 
 Induction of apoptosis by chemotherapeutic agents, such as DNA-damaging agents, 
topoisomerase inhibitors, and antimitotic agents, is largely mediated by the mitochondrial 
apoptotic pathways (2), which in turn increase the permeability of outer mitochondrial 
membrane. This involves release of mitochondrial apoptotic components, such as 
cytochrome c, apoptosis-inducing factor (AIF), second mitochondrial-derived activator of 
caspase, endonuclease G, and Omi1/HtrA2. The released apoptotic proteins initiate caspase 
activation and trigger caspase-mediated apoptotic DNA fragmentation and eventually cell 
death [29]. On the other hand, mammalian cells in a certain circumstance can undergo 
caspase-independent apoptosis that is mediated by the disruption of the mitochondrial 
membrane potential and the translocation of AIF and endonuclease G to nucleus where they 
induce chromatin condensation and/or large-scale DNA fragmentation. It has been reported 
that AIF mediates cell death through a Caspase-independent pathway. Mitochondrial AIF 
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translocates to the nucleus on death stimuli and initiates nuclear condensation that leads to 
large-scale chromatin fragmentation followed by the cell death [30-31]. 
 Apoptosis as a therapeutic goal offers advantages over non-apoptotic death 
mechanisms only if the therapeutic index or the availability of compounds that induce it is 
greater. In drug-curable malignancies, such as common pediatric leukemia and certain solid 
tumors, apoptosis is a prominent mechanism associated with the induction of tumor 
remission. In addition, the expression of apoptotic modulators within a tumor appears to 
correlate with its sensitivity to traditional cancer therapies. No strict correlation between the 
induction of apoptosis and a patient’s long-term prognosis has emerged, perhaps in part 
because the ability to achieve initial remission alone does not adequately predict long-term 
outcome [32] 
 A drug that activates apoptosis might achieve a suitable therapeutic index in several 
ways. First, it might activate a death cascade via a drug target that is uniquely expressed in 
a cancer cell. Alternatively, it might be delivered to the target tissue in a manner that is 
selective for the cancer cell. These 2 strategies have proved frustratingly difficult to achieve 
in any broad clinical sense during the past decades. A third and perhaps more promising 
approach is to exploit a pathway that is activated by oncogenes, in order to provoke 
apoptosis selectively in cancer cells [33]. 
 
 
1.3 DNA repair and therapeutic exploration 
 Living organisms have the crucial task to preserve their genome and faithfully 
transmit it across generations. Transmission of genetic information is constantly in a 
selective balance between the maintenance of genetic stability versus elimination of 
mutational change and loss of evolutionary potential. The DNA molecule is under the 
continuous attack of a multitude of endogenous and exogenous genotoxic insults and it has 
been estimated that every cell experiences up to 105 spontaneous or induced DNA lesions 
per day. Endogenous damage can result from DNA base lesions like hydrolysis 
(deamination, depurination, and depyrimidination) and alkylation (6-O-Methylguanine) or 
oxidation (8-oxoG) by intracellular ROS that can occur as by-products of mitochondrial 
respiration. Mutations can also arise during normal cellular metabolism for instance by 
erroneous incorporation of deoxyribonucleotides (dNTPs) during replication. 
Environmental sources of damage can be physical [e.g., ultraviolet (UV) light, ionizing 
radiations (IRs), and thermal disruption] or chemical (e.g., chemotherapeutic drugs, 
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industrial chemicals, and cigarette smoke) and their effects varies from the formation of 
cyclobutane pyrimidine dimers (CPDs) and pyrimidine 6-4 pyrimidone photoproducts (6-
4PPs) following UV exposure, to the introduction of single and double DNA strand breaks 
upon IR treatment, or to inter- and intrastrand DNA crosslinks, which result from various 
chemotherapeutic drugs [34]. 
 Poly (ADP-ribose) polymerase I (PARP1) is an abundant nuclear enzyme that 
catalyzes the formation of ADP-ribose polymers (PAR) on a host of protein substrates, 
including its own auto modification domain. Extensive research has revealed numerous 
PARP1 functions spanning a diverse array of nuclear processes, including DNA damage 
repair, chromatin remodeling, transcriptional regulation, telomere maintenance, and cell 
death. Owing primarily to the role of PARP1 (and the related but less abundant PARP2 and 
PARP3) in DNA damage repair, a number of PARP inhibitors are undergoing clinical 
development as anticancer agents with a focus on tumors with impaired homologous 
recombination (HR) capability and on combination regimens with DNA-damaging 
chemotherapy or radiation [35]. The function of PARP1 in DNA damage repair is complex 
and multifaceted, and includes contributions to multiple repair pathways including HR, base 
excision repair (BER), nucleotide excision repair (NER), and both classical and alternative 
nonhomologous end-joining. Preclinical studies have revealed combination activity of 
PARP inhibitors with DNA-alkylating agents, platinums, topoisomerase I inhibitors, and 
ionizing radiation. As the primary repair pathways for the lesions caused by each of these 
classes of agents differ, the mechanisms underlying their potentiation by PARP inhibitors 
is likely to be class specific. 
 Inhibition of DNA repair in cancer cells represents an attractive strategy for 
potentiating the cytotoxic effects of chemotherapy and radiation and therefore this has been 
a subject of scientific research for several decades. Of the known DNA repair inhibitors, 
Poly (ADP-ribose) polymerase inhibitors (PARPi) are furthest along in development and 
appear promising in a variety of cancer types, including breast and ovarian cancers. The 
first PARP enzyme was discovered over 40 years ago and PARP-1 is the most abundant and 
best-characterised member of the family of PARP enzymes. PARP-1 has a key role in the 
repair of single-strand breaks (SSBs), resulting from oxidative stress via the base excision 
repair/SSB repair (BER/SSBR) pathway [36]. 
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1.4 Thesis structural and overall impact 
 This whole study provides a novel method to identify new molecular target either 
using FDA-approved drug or new chemical synthetically drug for cancer therapeutic using 
combination between bioinformatics and biochemical approaches.  
 
Chapter 1 Introduction 
 In this chapter, an overview and background of this research is introduced including 
Bioinfomatics understanding, cancer and senescense, apoptosis in cancer, DNA repair and 
therapeutic exploration 
 
Chapter 2 Induction of senescence in cancer cells by 5-Aza-2-deoxycytidine: 
Bioinformatics and experimental insights to its targets. 
 
In this chapter, multimodule of 5-Aza-dC demethylating FDA-approved drug is 
explained very well by using combination of bioinfomatics and biochemical approach. 
 
 
Chapter 3 Conclusions and future researches 
In this chapter, the main results are summarized. In particular, the future research 
points were also directed. 
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Fig 1.1 Stimuli and effector scheme in senescence cells  
(Nature. 2014. 509: 439-446) 
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Fig 1. 2 An intrinsic pathway of apoptosis by activation of BH3-only protein  
(Trend in Cell Biology. 2013. 23(12)) 
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Fig 1.3 Schematic delineating the multifaceted nature of Poly (ADP) Ribose Polymerase 
(PARP): DNA repair, Chromatin Modification, Inflammation, Transcriptional 
Regulation, and Cell Death. 
(Cancers. 2013. 5: 943-958) 
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Chapter 2 
Induction of senescence in cancer cells by 5-Aza-2-
deoxycytidine: Bioinformatics and experimental insights 
to its targets 
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2.1 Introduction 
 
Cancer incidence is increasing rapidly worldwide and has prioritized anticancer drug 
discovery and development. In spite of remarkable progress in this field, only a small 
percent of drugs reach to clinical trials and even a smaller fraction of them develop to the 
drugs. This is because cancer is a diversive in its etiology and progression. Large databases 
on cancer genomics, transcriptomics and proteomic have established that although all 
cancers are accepted as a proliferative disease that resists apoptosis, they require multi-
module treatment. All cancers escape controls on normal cell proliferation due to lack of 
one or more functional tumor suppressor proteins; p53 is inactivated in the vast majority of 
cancers. Besides the local surgery, radiotherapy and chemotherapy are the two mainstream 
treatments for cancer. Since the new drugs have to undergo lengthy process of approval for 
safety or side effects, we set out in search of multi-module functions of established cancer 
drugs so that they could be put into wider use in cancer therapeutics. Acetylsalicylic acid 
known as aspirin, commonly used to treat pain, fever, and inflammation, has been shown to 
prevent heart attacks, strokes, and blood clot formation. It has also been reported to possess 
anti-hypertension and anticancer activities. Such studies have initiated a new field of cross-
functional research. An identification of new functionality of an existing drug is possible by 
Bio-Chem information technology. This approach has been widely used to analyze activities 
of a small molecule for the development of new drugs. DNA methylation is an important 
key of epigenetic modification to maintain genomic stability required in many biological 
steps including genomic imprinting, regulation of gene and chromatin remodeling. An 
abnormal pattern of DNA methylation has been reported in many tumor-derived cells 
leading to silencing of many tumor suppressor genes.  
5-Aza-2- deoxycytidine (5-AZA-dC) is a FDA-approved widely used 
hypomethylating anticancer drug. It causes global demethylation of cytosine in the C-5 
position of CpG rich promoters of tumor suppressor genes. Many studies have reported that 
5-AZA-dC induces DNA damage response signal- ing through activation of hallmark 
proteins including ATM, ATR (ATM-Rad3-related), checkpoint kinase 1 (CHK1), BRCA1, 
NBS1, and RAD51. In an earlier study, we reported that 5-AZA-dC interacts with mortalin 
and Pex3P causing activation of growth arrest signaling by inhibition of these proteins that 
occurred independently of its demethylation effect. It has also been shown that 
demethylation causes activation of miRNAs, the noncoding regulators that have been 
implicated in wide cellular processes including differentiation, proliferation, and 
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carcinogenesis. Of note, hundred target genes can be silenced by a single miRNA and hence, 
miRNA deregulation has been closely and complexly related to the process of 
carcinogenesis. Recently, we recruited 5-AZA-dC-induced senescence in miR- induced 
loss-of-function screening and identified miRNA-335 as a methylation regulatory miR and 
its role in tumor suppression through targeting CARF, a regulator of p53-HDM2-p21 
pathway, through mechanism independent of its demethylation effect. These reports have 
reflected the complexity of action of 5-AZA-dC. Carcinogenesis, tumor progression and 
metastasis have also been established as multifactorial phenom- ena involving loss and gain 
of function of tumor suppressor and oncogenes, respectively, by multiple and cross-talking 
pathways. It has been established that p53 is degraded by HDM2 by proteasomal 
degradation pathway and inactivated by binding to mortalin. Mortalin is widely distributed 
in the cytoplasm of normal cells, whereas the cancer cells show perinuclear localization. 
Human osteosarcoma cell lines when treated with 5-AZA-dC showed shift in mortalin 
staining pattern, from perinuclear to pancytoplasmic, and an upregulation and nuclear 
translocation of p53. Upregulation of HDM2 and mortalin has been reported in cancers that 
account for loss-of-function of p53 In agreement with these reports, drugs that abrogate 
p53-HDM2 and p53-mortalin interactions have been shown to cause growth arrest of cancer 
cells. In the present study, we conducted an analysis in search of new functions of 5-AZA-
dC using bio-chemo-informatics approach. The data suggested that 5-AZA-dC, independent 
to its demethylation activity, is a potential inducer of p53-p21 pathway and inhibits the 
growth of cancer cells.  
 
2.2 Material and Methods 
2.2.1 Prediction protein target and bioactivity of 5-AZA-dC 
The structure of 50-Aza-20-deoxycytidine (5-AZA-dC) was drawn and converted into 
a simplified molecular input line entry system (SMILES) by PubChem editor software [1]. 
SMILES structure was then used to predict the targeted protein and its bioactivity. The 
protein of targeted 5-AZA-dC was predicted by structural similarity toward the drug 
database by applying SuperPred method [2]. Meanwhile, the prediction of 5-AZA-dC 
bioactivity was made by comparing the active structure with the drug database by 
Molinspiration Cheminformatics 2016 and PASS online [3].  
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2.2.2 Protein network and biological process analyses  
The predicted proteins showed binding capability with 5-AZA-dC are CXCR4, 
POLB, POLA1 and HDM2. These proteins were then analyzed for their interactions with 
other proteins (protein network) to determine their biological function in a cell. Protein 
network analysis was performed by Cytoscape software [4], based on the human protein in 
BIOGRID database [5]. Proteins that were interacting with the targeted proteins were 
analyzed for their biological function by using an algorithm of A Biological Network Gene 
Ontology tool (BINGO) [6].  
 
2.2.3 Analysis molecular docking  
The ligands used for docking analyses were 5-AZA-dC and POLB, POLA1, MDM2, 
CXCR4 protein inhibitors. SMILE structure of 5- AZA-dC was converted to the 3D 
structure in the format of Protein Data Bank (PDB) by Discovery Studio software (“Dassault 
Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 4.5, San Diego: 
Dassault Systèmes, 2015.,” n.d.). The structure was then used as a ligand for docking. The 
structure of 5,6-dihydroxy-3- carboxyphenylester (BDBM50 293303; CHEMBL498103) 
Gallic acid as POLB/POLA1 inhibitor and Chalcone 4 as CXCR4 inhibitor were taken from 
BindingDB database [7]. Meanwhile, the structure of receptor protein was retrieved from 
protein data banks with access codes as follows 4oq3 (MDM2), 5bol (POLB), 4q5 v 
(POLA1), and 3oe6 (CXCR4). The proteins were then prepared by Discovery Studio 
software. Interactions between proteins (receptors) with the small molecule (ligand) were 
performed by Autodoc Vina integrated into the Pyrx software [8-9]. Docking was performed 
by imposing receptors as rigid molecules while the ligand molecule was set flexible and 
graded in the active site. Results of docking and bonding interactions between ligands and 
receptors were analyzed by Discovery Studio software.  
 
2.2.4 Cell culture, cell growth inhibition analysis and immunostaining  
Human osteosarcoma (U2OS) and breast carcinoma (MCF7) cells were obtained from 
Japanese Collection of Research Bioresources (JCRB, Japan). Cells were treated with 5-
AZA-dC (10 mM) and maintained in DMEM (Dulbecco's Modified Eagle's Medium) (Life 
Technologies, Carlsbad, CA, USA)-supplemented with 10% fetal bovine serum and 
antibiotics at 5% CO2 and 95% air in a humidified incubator for 72 h. Cells were harvested 
every day and counted by hemocytometer to examine the growth. Immuno-staining was 
performed on fixed (treated with pre-cooled methanol/acetone 1:1, vol/vol. for 5 min on ice) 
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cells grown on glass coverslips. The fixed cells were washed with cold phosphate-buffered 
saline (PBS) 3 times and permeabilized using 0.2% Triton X-100 in PBS for 10 min. The 
permeabilized cells were blocked with 2% bovine serum albumin (BSA) in PBS for 30 min 
and incubated with anti-MDM2 (HDM2-323) and p53 (FL-393) (Santa Cruz, CA, USA) 
antibodies followed by washing in 0.2% Triton X-100 in PBS 3 times, 10 min each, and 
incubation with Alexa 488- conjugated goat anti-mouse or Alexa-594-conjugated goat anti-
rabbit antibodies (Molecular Probes, Invitrogen).They were then washed in 0.2% Triton X-
100 in PBS 3 times, 10 min each. Nuclear staining was performed with Hoechst 33342 
(Sigma) for 5 min in dark followed by three times washing. The cells were overlaid with a 
coverslip containing Fluoromount (Difco/BD, Franklin Lakes, and NJ) and observed under 
a Carl Zeiss microscope (Axiovert 200 M, Tokyo, Japan).  
 
2.2.5 Cell viability in response to drugs  
U2OS cells were seeded in 96-well plate for 24 h. At about 65– 70% confluency, 10 
mM 5-AZA-dC treatment was given for the next 24 h followed by 5-Flourourasil (20, 30 
and 40 mM), Nacodazole (120, 160 and 200 mM), and Curcumin (10, 30 and 50 mM) 
treatment for 24 h. DMSO in equal volume was prepared as a control. Viability of cells was 
measured following manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA) 
and as described earlier [10].  
 
2.3 Results and Discussion 
I examined the possibility of new functions of 5-AZA-dC (the structure is shown in 
Fig. 1A) by bio-chemo-informatics analyses and predicted a new mechanism of its 
anticancer activity. It was predicted that 5-AZA-dC serves as an inhibitor of CXCR4, 
HDM2, POLB, and POLA1 resulting in up-regulation of p53 pathway, growth arrest or 
apoptosis (Fig. 1B-E and 2B). Moreover, it was predicted that 5-AZA-dC might induce p53 
by disrupting p53-HDM2 binding complex. The docking analysis showed that 5-AZA-dC 
could bind to CXCR4, HDM2, POLB and POLA1 at its active site, where the known 
inhibitors bind (Fig. 2A). Superimpose showed that 5-AZA-dC occupied the same position 
as a known inhibitor bound to proteins (Fig. 2A, bottom panel). The 5-AZA-dC binds to the 
binding site of 6-dihydroxy-3- carboxyphenylester, gallic acid and chalcone on PASS online 
analysis predicted that 5-AZA-dC may target several proteins involved in DNA damage and 
p53 tumor suppressor pathway (Fig. 1B). SuperPred analysis result suggested that it binds 
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to POLA1, POLB, and CXCR4 (Fig. 1C). Molinspiration analysis predicted its inhibitory 
action on several enzymes, and as GPCR ligand (Fig. 1D).  
Of note, SuperPred analysis showed that 5-AZA-dC could target CXCR4 protein (Fig. 
1C) in line with the predicted outcomes of molinspiration i.e. the drug has an activity as 
GPCR ligand (Fig. 1D). G protein-coupled receptor (GPCR) is an orphan protein that has 
recently been focused in the pharmaceutical industry as a novel pro-apoptosis protein [11-
14]. Together with these analyses, in order to depict the role of 5-AZA-dC in cell 
physiology, I examined the interacting protein patterns of predicted protein targets of 5-
AZA-dC. The Interactome analysis by BINGO revealed that the targets of 5-AZA-dC were 
involved in various mechanisms including apoptosis, DNA damage response, and p53/p21 
signaling (Fig. 1E), and endorsed its function as an anticancer drug. Furthermore, CXCR4, 
POLA1, POLB, and HDM2 regulates p53-p21 pathway, apoptosis and growth arrest. I also 
examined the potential of 5-AZA-dC as HDM2 inhibitor leading to activation of p53 in cell-
based assays. Fig. 3A shows the HDM2 and p53 leading to degradation of p53 via 
proteasome. 5-dAZA-dC-treated cells in a well were examined for senescence-associated  
β-galactoside staining As shown in Fig. 3B, the treated cells showed intense β-galactoside 
staining suggesting the induction of senescence. Co-immuno-staining using anti-HDM2 and 
anti-p53 antibodies showed downregulation of HDM2 and upregulation of p53 in 5-AZA-
dC-treated cells (Fig. 3C). The latter was also endorsed by Western blotting with anti-p53 
antibody (Fig. 3D) and p53 dependent reporter assays (Fig. 3E). Since cancer chemotherapy 
often involves a combination of drugs, we next examined if 5-AZA-dC could potentiate the 
effect of other three (5FU, Nocodazole, and Curcumin) anticancer drugs. To my surprise, I 
found that the combination treatment did not result in any accumulative/ synergistic effect 
rather caused minor resistance to all the three drugs used (Fig. 4 A-C).  
In the present report, I show that 5-AZA-dC targets POLA1, POLB, CXCR4 and 
HDM2 proteins. POLA1 and POLB play crucial functions in base excision repair (BER) in 
response to genotoxic and cytotoxic stresses. HDM2 is an established antagonist of tumor 
suppressor p53 protein. This complex abolishes the activation of p53 as a tumor suppressor 
(Fig. 3A). As expected, HDM2 targeting caused activation of p53 protein (key 
transcriptional regulator of stress response, including DNA damage). Together, POLA1, 
POLB and p53 proteins are predicted to be involved in cell response to 5- AZA-dC. 
Furthermore, GPCR protein, an important player of cell proliferation and apoptosis was 
identified as a 5-AZA-dC target.  
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Blocking of GPCR receptor has been shown to inhibit cell division and metastasis 
resulting in growth arrest in cancer cells. CXCR4 protein is a member of GCPR involved 
in cancer pathways (KEGG: hsa05200) [15]. It regulates the intracellular calcium ion levels 
and enhances MAPK1/MAPK3 activation (Uniprot: P61073) (Magrane and UniProt 
Consortium, 2011). Blocking of CXCR4 protein induces cell death or growth arrest and 
hence has been proposed as a target for cancer drug development [16-18]. My study 
suggested that demethylation-independent targeting of proteins by 5-AZA-dC might also be 
a promising strategy for cancer therapy. Through bio-chemo-informatics approach, I 
identified a new function of 5-AZA-dC as a p53 inducer, mediated by inhibition of HDM2, 
an established antagonist of p53. Besides having the ability to demethylate the genome, 5-
AZA-dC was also predicted to inhibit mortalin [19]. I report that an increase in the level of 
p53 in 5-AZA-dC-treated cells is mediated by down-regulation of HDM2. Besides 
inhibiting MDM2 and mortalin, 5- AZA-dC was also able to inhibit DNA polymerases and 
DNA repair signaling. Cancer cells tend to have a high metabolism, and release free radicals 
that can cause DNA damage [20]. Previous research has indicated that several noncoding 
tumor suppressors (miRNAs) are regulated by p53 [21-23]. Interestingly, I investigated new 
regulatory targets by loss-of-function miRNA screening and found induction of miRNA-
335 that targeted CARF (collaborator ARF) and several cell cycle regulatory proteins 
leading to growth suppression in cancer cells. Transfection of miRNA-335 to cells prior to 
5-AZA-dC treatment showed down-regulation of CARF, p53, and p16INK4A expressions. 
In contrast, MDM2 and p21WAF1 remained high that led to cell cycle arrest [24]. Adequate 
expression of CARF itself is necessary for cell survival mechanism while overexpression 
abolished p53 protein expression [25]. 
Taken together, 5-AZA-dC, an established demethylating drug leads to growth arrest 
of cancer cells through mechanisms involving direct targeting of proteins leading to 
activation of p53 pathway. Combination of more than one anticancer agents is often used to 
control the progress and metastasis of cancers. The cocktail of anticancer drugs is thought 
to be more powerful than any single drug administration [26-27]. I performed drug 
combination by sensitizing cells by 5-AZA-dC for 24 h followed by addition of three 
anticancer drugs (Nacodazole, 5FU and Curcu-min) independently. Surprisingly, the data 
showed that prior treatment of 5AZA-dC caused resistance to the three drugs. The possible 
interpretation of this effect could be that these drugs work on proliferating cells, growth 
arrest caused by prior 5-AZA-dC treatment resulted in subsequent drug resistance. This 
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finding suggested that the combination of 5-AZA-dC with other anticancer drugs should be 
selected very carefully so as not to yield drug resistance phenotype.  
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Fig 2.1 5-AZA-dC (A) that has a role in upregulation of p53 (B) was predicted to bind to 
DNA polymerase (C) and inhibit the activity of several enzymes (D). The drug 
induces apoptosis and growth arrest through several pathways especially DNA 
damage response through p53 signalling pathway (E). 
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Fig 2.2 5-AZA-dC binds to the active sites of CXCR4, MDM2, POLB and POLA1. The 
bindings of 5-AZA-dC to these proteins share similar pattern and position with their 
inhibitor (A). The data suggested that 5-AZA-dC potentially block the activity of 
MDM2, CXCR4 POLB, and POLA1 (B). 
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Fig 2.3 Schematic drawing of HDM2-p53 pathway (A). β-galactoside staining indicates 
cells senescence (B). Immunostaining showing up-regulation of p53 protein induced 
in response of 5-AZA-dC treatment in U2OS and MCF cell lines (C). Western 
blotting of p53 (D). Induction of p53 showed by p53-dependent reporter assay (E). 
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Fig 2.4 5-AZA-dC caused resistance to anticancer drugs (5-Fluorourasil (5FU), Nocodazole 
and Curcumin)
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4.1 Conclusion 
In this thesis I used two anticancer drugs, (i) FDA-approved drug (5-Aza-dC) 
which shown cause demethylating in cancer cells and. By using Bioinformatics and 
Biochemical combination approaches that helps us to understand better new module 
of 5-Aza-dC. 
Independently from work on 5-Aza-dC we conclude that: 
1. 5-Aza-dC is targeting some enzyme involved in apoptosis including POLA1, POLB 
and CXCR4 
2. Activates p53 protein expression 
3. Combination with others anticancer drugs caused cells resistant with treatment 
comparing each treatment alone 
 
4.1 Future work 
For 5-Aza-dC, more deeply observations need to be done regarding its effects 
on POLA1, POLB, and CXCR4 and in vivo experiment.  
  
 
